Previous 10 | Next 10 |
2023-12-16 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared webcast information for the virtual Immunology R&am...
STAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma (CTCL) and Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect demonstrated in tumor as well as blood...
Atopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial in Hidradenitis Suppurativa (HS) Topline Phase 2 data from both the AD and HS trials expected in the first half of 2025 ...
2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...
2023-11-24 02:56:01 ET Summary Arvinas is a leading company in developing protein degraders, with a depressed share price, drugs in advanced study phases, and ample cash reserves. Arvinas is focused on oncology, particularly breast and prostate cancer, setting it apart from compet...
KT-474 showed evidence of robust target degradation and pathway inhibition with a favorable safety profile in healthy volunteers and patients Trial showed encouraging impact on disease burden and symptoms in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), with a systemic a...
2023-11-12 02:27:10 ET Summary Kymera's KT-474 shows promise in Phase I for HS and AD, balancing clinical potential with financial challenges. Despite revenue decrease, Kymera's strong current ratio and ample cash reserves provide short-term financial stability. Market sentime...
2023-11-04 13:10:18 ET Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript November 02, 2023 08:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Bruce Jacobs - CFO Co...
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through July 10, 2023 cut-off Updated data to be presented at the American Society of Hematology (ASH) 65 th Annual Meeting and Exposition on December 10, 2023 WATERTOWN, Ma...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...